Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: A 5-year clinical trial

•240 weeks of TDF monotherapy provided an increasing virologic response rate in patients with multidrug-resistant HBV. •Virologic breakthrough was rare and not associated with emergence of additional resistance mutations. •The HBeAg seroconversion rate was very low and no patient achieved HBsAg seroclearance up to week 240. •Prolonged continuous treatment may be needed to maintain viral suppression in these patients. •Progressive and significant...